Skip to content

ADVANCE- Automated Detection and Volumetric Assessment of ICH

Automated Detection and Volumetric Assessment of Intracerebral Hemorrhage Using Artificial Intelligence- Multicenter Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04733638
Enrollment
1000
Registered
2021-02-02
Start date
2021-01-26
Completion date
2023-04-28
Last updated
2024-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intracerebral Hemorrhage

Keywords

Artificial Intelligence, ICH

Brief summary

To evaluate the performance of the Viz ICH VOLUME algorithm.

Detailed description

To evaluate the performance of the Viz ICH VOLUME algorithm to: 1. detect the presence of ICH on brain imaging, 2. measure the volume of ICH on brain imaging, 3. and to assess the algorithm processing time, 4. and the difference in time to notification, time to treatment, and clinical outcomes in comparison to standard of care.

Interventions

DEVICEViz ICH VOLUME

Viz ICH VOLUME software is a module that identifies and segments Intraparenchymal Hemorrhage (IPH) from NCCT imaging. This software is for investigational use in the study and is not FDA cleared. For subjects who undergo a brain scan, Viz will use deep learning algorithms to analyze computed tomography (CT) or magnetic resonance (MR) images of the brain for ICH in parallel to standard of care image interpretation. If a suspected ICH is detected, Viz will perform an automatic volumetric analysis and will send a notification to a specialist, such as a neurointerventionalist or a neurosurgeon. Notifications prompt the specialist to review the patient's case. Additionally, non-diagnostic previewing of DICOM images, and HIPAA-compliant text messaging and phone calls are available in the software platform. Viz ICH VOLUME is not intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man.

Sponsors

Viz.ai, Inc.
Lead SponsorINDUSTRY

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patients (18 and older) * Presenting with symptoms suspicious for an acute stroke / intracranial hemorrhage * Having a complete imaging data set including NCCT +/- MRI, CTA and/or MRA

Exclusion criteria

* Subjects with poor or incomplete brain imaging.

Design outcomes

Primary

MeasureTime frameDescription
Algorithm PerformanceUp to 10 minutesSensitivity and specificity of Viz ICH VOLUME in detecting ICH compared to standard of care evaluation.

Secondary

MeasureTime frameDescription
Time to NotificationUp to 10 minutesTime in minutes from CT imaging to time an interventionalist was notified
Time to Treatmentup to 1 day (1440 minutes)Time in minutes from CT imaging to start time of treatment
Algorithm Processing TimeUp to 10 minutesTotal run time in minutes for the algorithm to process the CT scan following receipt
In Hospital ComplicationsHospital admit to discharge, up to 30 daysOccurrence of stroke-related or stroke treatment-related complications while in hospital
Modified Rankin Scale (mRS) at Discharge and 90 Days90 daysThe Modified Rankin Score (mRS) is a 6 point disability scale with possible scores ranging from 0 to 5. A separate category of 6 is usually added for patients who expire. A score of 0 is a patient with no residual symptoms. Scores increase with severity to 5 which equals severe disability.
Length of StayHospital admit to discharge, up to 30 daysNumber of days in hospital

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026